EGFR and esophageal squamous cell carcinoma: Current approaches to improve ESCC outcomes focus on addressing key mutations and pathways involved in ESCC, for example, programmed death receptor 1/programmed cell death‐ligand 1 (PD‐1/PD‐L1) and epidermal growth factor receptor (EGFR) signaling.36, 39